CD274 and neoplasm: (2023) developed a modular platform using poly (glutamic acid) scaffolds for noncovalent Fc-domain conjugation, generating anti-PD-L1 conjugates (aPDL1-P-MMAE, DAR = 40.7) achieving 98.5% tumor growth inhibition in MC38 CRC models without systemic toxicity (71).